Edition:
United States

Cardiome Pharma Corp (CRME.OQ)

CRME.OQ on NASDAQ Stock Exchange Capital Market

3.15USD
28 Sep 2016
Change (% chg)

-- (--)
Prev Close
$3.15
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
30,126
52-wk High
$9.50
52-wk Low
$2.80

CRME.OQ

Chart for CRME.OQ

About

Cardiome Pharma Corp. (Cardiome) is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of cardiovascular therapies for heart disease. The Company's segments are Europe and Rest of World. Cardiome has two marketed, in-hospital, cardiology products, which include BRINAVESS... (more)

Overall

Beta: 0.89
Market Cap(Mil.): $63.88
Shares Outstanding(Mil.): 20.36
Dividend: --
Yield (%): --

Financials

  CRME.OQ Industry Sector
P/E (TTM): -- 37.66 37.54
EPS (TTM): -1.11 -- --
ROI: -73.46 14.54 13.98
ROE: -190.95 15.32 14.88

BRIEF-Stonepine Capital reports 5.6 pct passive stake in Cardiome Pharma

* Stonepine Capital reports 5.6 pct passive stake in Cardiome Pharma as of sept 6 - sec filing Source text: (http://bit.ly/2cEUZHM) Further company coverage:

Sep 16 2016

BRIEF-Cardiome prices offering of 10 mln shares at $3.00 per share

* Cardiome announces pricing of public offering of 10,000,000 common shares

Jul 26 2016

BRIEF-Cardiome announces proposed public offering

* Cardiome announces proposed public offering of common shares

Jul 25 2016

BRIEF-Cardiome announces term loan agreement with CRG-Managed Funds

* Pharma Corp says has entered into a term loan agreement with CRG-Managed Funds

Jun 14 2016

BRIEF-Cardiome Pharma reports Q1 2016 financial results

* Cardiome reports first quarter 2016 financial results Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

May 13 2016

BRIEF-Cardiome Q1 loss per share $0.06

* Anticipate our first commercial sales of XYDALBA this year and a larger commercial roll-out during 2017

May 13 2016

U.S. RESEARCH ROUNDUP-Weatherford, General Motors, Endo International

May 6 Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Total System Services, Ubiquiti Networks and Advance Auto Parts, on Friday. HIGHLIGHTS * United Rentals Inc : Goldman Sachs cuts to sell from neutral * Weatherford International : Seaport Global Securities raises to buy from neutral * Endo International Plc : Mizuho Securities cuts to underperform from neutra

May 06 2016

BRIEF-Cardiome and Allergan announce Xydalba(tm) licensing agreement in international markets

* Cardiome and allergan announce xydalba(tm) (dalbavancin) licensing agreement in international markets

May 05 2016

BRIEF-Cardiome Pharma publishes independent study comparing BRINAVESS to Ibutilide in Patients

* Publication of independent study comparing BRINAVESS to Ibutilide in patients with recent-onset atrial fibrillation

Mar 31 2016

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $117.46 -1.93
Pfizer Inc. (PFE.N) $33.42 -0.57
Novartis AG (NOVN.S) CHF77.25 -1.30
Bayer AG (BAYGn.DE) €88.30 -0.96
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €68.03 -0.29
AstraZeneca plc (AZN.L) 5,026.00p -96.00
GlaxoSmithKline plc (GSK.L) 1,647.50p -7.50
Gilead Sciences, Inc. (GILD.OQ) $78.07 -0.90
Boston Scientific Corporation (BSX.N) $23.35 -0.40

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : MacroRisk Analytics/EconomicInvestor
$25.00
Provider : ValuEngine, Inc.
$25.00
Provider : S&P Capital IQ Quantitative Report
$115.00
Provider : Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.